A phase 2 trial of verubulin for recurrent glioblastoma: a prospective study by the brain tumor investigational consortium (BTIC)

CBTRUS Statistical Report: Primary Brain and Central Nervous System Tumors Diagnosed in the United States in 2006-2010

(2013) Q. T. Ostrom et al.   NEURO-ONCOLOGY

Modulation of Chemotherapeutic Efficacy by Vascular Disrupting Agents: Optimizing the Sequence and Schedule

(2012) Eunice S. Wang et al.   JOURNAL OF CLINICAL ONCOLOGY

Resistance and Escape From Antiangiogenesis Therapy: Clinical Implications and Future Strategies

(2012) Justin N. Bottsford-Miller et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase I trial of verubulin (MPC-6827) plus carboplatin in patients with relapsed glioblastoma multiforme

(2012) Kenneth F. Grossmann et al.   JOURNAL OF NEURO-ONCOLOGY

Evolving strategies: future treatment of glioblastoma

(2011) Marc Chamberlain   Expert Review of Neurotherapeutics

Clinical Development of Vascular Disrupting Agents: What Lessons Can We Learn From ASA404?

(2011) Patricia M. LoRusso et al.   JOURNAL OF CLINICAL ONCOLOGY

Discovery of N-methyl-4-(4-methoxyanilino)quinazolines as potent apoptosis inducers. Structure–activity relationship of the quinazoline ring

(2010) Nilantha Sirisoma et al.   BIOORGANIC & MEDICINAL CHEMISTRY LETTERS

Survival of Patients with Newly Diagnosed Glioblastoma Treated with Radiation and Temozolomide in Research Studies in the United States

(2010) S. A. Grossman et al.   CLINICAL CANCER RESEARCH

Updated Response Assessment Criteria for High-Grade Gliomas: Response Assessment in Neuro-Oncology Working Group

(2010) Patrick Y. Wen et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase I Clinical Trial of MPC-6827 (Azixa), a Microtubule Destabilizing Agent, in Patients with Advanced Cancer

(2010) A.-M. Tsimberidou et al.   MOLECULAR CANCER THERAPEUTICS

Bevacizumab Alone and in Combination With Irinotecan in Recurrent Glioblastoma

(2009) Henry S. Friedman et al.   JOURNAL OF CLINICAL ONCOLOGY

Discovery ofN-(4-Methoxyphenyl)-N,2-dimethylquinazolin-4-amine, a Potent Apoptosis Inducer and Efficacious Anticancer Agent with High Blood Brain Barrier Penetration

(2009) Nilantha Sirisoma et al.   JOURNAL OF MEDICINAL CHEMISTRY

Salvage therapy with single agent bevacizumab for recurrent glioblastoma

(2009) Marc C. Chamberlain et al.   JOURNAL OF NEURO-ONCOLOGY

Role of a second chemotherapy in recurrent malignant glioma patients who progress on bevacizumab

(2009) Eudocia C. Quant et al.   NEURO-ONCOLOGY

Phase II Trial of Single-Agent Bevacizumab Followed by Bevacizumab Plus Irinotecan at Tumor Progression in Recurrent Glioblastoma

(2008) Teri N. Kreisl et al.   JOURNAL OF CLINICAL ONCOLOGY

Progression-free survival: An important end point in evaluating therapy for recurrent high-grade gliomas

(2008) Kathleen R. Lamborn et al.   NEURO-ONCOLOGY

Bevacizumab for recurrent malignant gliomas: Efficacy, toxicity, and patterns of recurrence

(2008) A. D. Norden et al.   NEUROLOGY

Malignant Gliomas in Adults

(2008) Patrick Y. Wen et al.   NEW ENGLAND JOURNAL OF MEDICINE